Two Sigma Advisers’s Maravai LifeSciences MRVI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $5.36M | Sell |
2,224,594
-13,406
| -0.6% | -$32.3K | 0.01% | 716 |
|
|
2025
Q1 | $4.95M | Buy |
2,238,000
+2,021,500
| +934% | +$4.47M | 0.01% | 799 |
|
|
2024
Q4 | $1.18M | Sell |
216,500
-453,000
| -68% | -$2.47M | ﹤0.01% | 1386 |
|
|
2024
Q3 | $5.56M | Sell |
669,500
-289,300
| -30% | -$2.4M | 0.01% | 674 |
|
|
2024
Q2 | $6.87M | Sell |
958,800
-404,000
| -30% | -$2.89M | 0.02% | 654 |
|
|
2024
Q1 | $11.8M | Sell |
1,362,800
-80,100
| -6% | -$694K | 0.03% | 484 |
|
|
2023
Q4 | $9.45M | Sell |
1,442,900
-290,600
| -17% | -$1.9M | 0.02% | 550 |
|
|
2023
Q3 | $17.3M | Sell |
1,733,500
-748,100
| -30% | -$7.48M | 0.04% | 344 |
|
|
2023
Q2 | $30.8M | Buy |
2,481,600
+974,500
| +65% | +$12.1M | 0.08% | 229 |
|
|
2023
Q1 | $21.1M | Buy |
1,507,100
+383,400
| +34% | +$5.37M | 0.05% | 319 |
|
|
2022
Q4 | $16.1M | Buy |
1,123,700
+665,400
| +145% | +$9.52M | 0.04% | 396 |
|
|
2022
Q3 | $11.7M | Buy |
458,300
+165,800
| +57% | +$4.23M | 0.03% | 460 |
|
|
2022
Q2 | $8.31M | Buy |
292,500
+176,000
| +151% | +$5M | 0.02% | 567 |
|
|
2022
Q1 | $4.11M | Buy |
116,500
+86,100
| +283% | +$3.04M | 0.01% | 892 |
|
|
2021
Q4 | $1.27M | Buy |
30,400
+24,800
| +443% | +$1.04M | ﹤0.01% | 1433 |
|
|
2021
Q3 | $275K | Buy |
+5,600
| New | +$275K | ﹤0.01% | 2146 |
|
|
2021
Q2 | – | Sell |
-57,600
| Closed | -$2.05M | – | 2601 |
|
|
2021
Q1 | $2.05M | Buy |
57,600
+600
| +1% | +$21.4K | 0.01% | 1254 |
|
|
2020
Q4 | $1.6M | Buy |
+57,000
| New | +$1.6M | ﹤0.01% | 1372 |
|